Oct 14 (Reuters) – Australian biotech CSL (CSL.AX) stated on Thursday it was dedicated to its settlement for the manufacturing of about 50 million doses of AstraZeneca’s (AZN.L) COVID-19 vaccine into 2022.
The announcement got here after a media report stated the British drugmaker’s vaccine, Vaxzevria, will not be manufactured in Australia due to demand for vaccines of Pfizer (PFE.N) and Moderna (MRNA.O). [nL4N2R91XR]
Pfizer and Moderna have established a market dominance by utilizing mRNA-based COVID-19 vaccine know-how to combat the pandemic.
CSL, in a brief statement, added that greater than 20 million of the doses have already been produced, and it’s anticipated that the remaining manufacturing shall be accomplished early subsequent yr.
Cafes, gyms and eating places in Sydney welcomed again absolutely vaccinated clients earlier this week after practically 4 months of a lockdown, as Australia goals to start dwelling with the coronavirus and steadily reopen with excessive charges of inoculation.